ORKA

Oruka Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its lead program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, psoriatic arthritis (PsA), and other conditions. ORKA-001 is an extended half-life monoclonal antibody (mAb) designed to target IL-23p19. IL-23 is a pro-inflammatory cytokine that plays a critical role in the proliferation and development of T helper 17 (Th17) cells, which are the primary drivers of several autoimmune and inflammatory disorders, including PsO. IL-23 is composed of two subunits: a p40 subunit and a p19 subunit. ORKA-002 is an extended half-life mAb designed to target IL-17A and IL-17F (IL-17A/F).

Wall Street analysts forecast ORKA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ORKA is 48.25 USD with a low forecast of 40.00 USD and a high forecast of 63.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Oruka Therapeutics Inc revenue for the last quarter amounts to -34.11M USD, increased 15.81 % YoY.

Oruka Therapeutics Inc. EPS for the last quarter amounts to -21701000.00 USD, decreased -38.05 % YoY.

Oruka Therapeutics Inc (ORKA) has 28 emplpoyees as of December 15 2025.

Today ORKA has the market capitalization of 1.46B USD.